EGFR and non-small cell lung carcinoma: As observed in the total NSCLC patient population, survival with EGFR-TKI treatment in EGFRm-positive patients was also longer than with chemotherapy alone (adjusted HR[EGFR-TKI]=0.19 [95% CI: 0.12–0.29], adjusted HR (chemotherapy)=0.50 [95% CI: 0.30–0.85]), and both significantly prolonged OS compared with best supportive care.